The Valley Desk

LetterBritish journal of haematologyPublished

A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS

22 of 31 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Letter
Venue
British journal of haematology
Published
Subject terms
Acute myeloid leukaemia; Myelodysplastic Syndromes; Phase 1; Dihydroorotate Dehydrogenase; Jnj‐74856665
PubMed ID
40598790
PubMed Central ID
PMC12379018
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal